# Oxaliplatin

## Orectalip inj 50mg/10mL

| 藥物代碼 | IORE |
| :--- | :--- |
| 適應症 | Adjuvant treatment of stage III colon cancer after complete resection of primary tumor and advanced colorectal cancer \(in combination with infusional fluorouracil and leucovorin\). |
| 副作用 | Nausea, vomiting, diarrhea; anemia, leucopenia, granulocytopenia, thrombocytopenia; peripheral neuropathies; fever, rash, anorexia. Gastrointestinal: Abdominal pain \(monotherapy, 31%; combination therapy, up to 39% \), Constipation \(combination therapy, up to 32% \), Diarrhea \(monotherapy, 46%; combination therapy, up to 76% \), Loss of appetite \(monotherapy, 20%; combination therapy, up to 35% \), Nausea \(monotherapy, 64%; combination therapy, up to 83% \), Stomatitis \(monotherapy, 14%; combination therapy, up to 42% \), Vomiting \(monotherapy, 4%; combination therapy, up to 64% \)Hematologic: Anemia \(monotherapy, 64%; combination therapy, up to 81% \), Neutropenia, All grades \(monotherapy, 7%; combination therapy, up to 81% \)Musculoskeletal: BackacheRespiratory: Cough \(monotherapy, 11%; combination therapy, up to 35% \)Other: Fatigue \(monotherapy, 61%; combination therapy, up to 70% \), Fever \(monotherapy, 25%; combination therapy, up to 29% \) |
| 禁忌 | Hypersensitivity to oxaliplatin, other platinum-containing compounds, or any component of the formulation. Pregnancy, breast-feeding; severe renal impairment \(CrCl &lt;30 mL/minute\) |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adult Adjuvant therapy 85 mg/m2 IV every 2 week for 6 month \(12 cycles\). Metastatic colorectal cancer 85 mg/m2 IV every 2 weeks. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | 藥品仿單:懷孕及授乳者禁用。 |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選 仿單建議 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 1. IV: Dilute in 250 to 500 mL D5W \(do not use NS\) to a final concentration &gt; 0.2 mg/mL. Administer as IV infusion over 2-6 hours. 2. Flush infusion line with D5W prior to administration of any concomitant medication. |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射的器具不可含有鋁。本藥品不可使用含有氯的稀釋溶液 \(例如：N/S\)，給藥時避免和鹼性藥物\(例如：5-FU\)使用相同管路。 3. 稀釋後的輸注溶液在室溫下安定性維持24小時。 4. 監測CBC、腎功能，注意病人是否有呼吸方面的異常症狀。 5. 定期神經學檢測。 |

